Arylpiperazine derivatives useful as uroselective...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 207/40 (2006.01) A61K 31/495 (2006.01) C07D 207/404 (2006.01) C07D 207/408 (2006.01) C07D 211/88 (2006.01) C07D 401/06 (2006.01)

Patent

CA 2338317

Novel piperazine derivatives substituted on one nitrogen by an aromatic system and on the other nitrogen by (2,5-dioxopyrrolidin)-1-yl) alkanes or (2,6- dioxopiperidin-1-yl) alkanes have been found to exhibit selective .alpha.1A adrenergic activity. The compounds are useful for treatment of disease conditions, such as peripheral vascular disease, congestive heart failure, hypertension and especially benign prostatic hypertrophy.

L'invention concerne de nouveaux dérivés de pipérazine substitués dans un azote par un système aromatique et dans l'autre azote par des (2,5-dioxopyrrolidine)-1-yl) alcanes ou des (2,6-dioxopyrrolidine)-1-yl) alcanes, qui manifestent une activité sélective .alpha.¿1A? adrénergique. Ces composés sont utiles pour traiter des états pathologiques tels que les acrosyndromes, l'insuffisance cardiaque globale, l'hypertension et tout particulièrement l'hypertrophie prostatique bénine.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Arylpiperazine derivatives useful as uroselective... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylpiperazine derivatives useful as uroselective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylpiperazine derivatives useful as uroselective... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1816285

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.